keyword
MENU ▼
Read by QxMD icon Read
search

hepatocellular carcinoma stage system

keyword
https://www.readbyqxmd.com/read/27914119/fibrinogen-and-d-dimer-levels-elevate-in-advanced-hepatocellular-carcinoma-high-pretreatment-fibrinogen-levels-predict-poor-outcomes
#1
Zhikun Liu, Haijun Guo, Feng Gao, Qiaonan Shan, Jie Li, Haiyang Xie, Lin Zhou, Xiao Xu, Shusen Zheng
AIM: Plasma fibrinogen and D-dimer have been reported to predict survival in several types of malignancies. The aim of this study is to investigate their predictive value in patients with hepatocellular carcinoma (HCC). METHODS: We retrospectively analyzed plasma fibrinogen and D-dimer levels from 252 subjects: control (n = 20), hepatitis (n = 20), cirrhosis (n = 20), and HCC (n = 192) subjects. The clinical involvement and prognostic value of fibrinogen and D-dimer was analyzed in HCC subjects...
December 3, 2016: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/27899961/the-ras-raf-mek-erk-signaling-pathway-and-its-role-in-the-occurrence-and-development-of-hcc
#2
Lei Li, Guo-Dong Zhao, Zhe Shi, Li-Li Qi, Li-Yuan Zhou, Ze-Xian Fu
Hepatocellular carcinoma (HCC) is the fifth most common tumor worldwide and has a very poor prognosis. Its occurrence has been on the increase in recent years. Surgical resection and liver transplantation are the primary methods of treatment for HCC patients, but can only be applied to 15% of patients. The median survival time of unresectable or metastasizing HCC patients is only a few months. Existing systemic treatment methods are not effective for advanced HCC patients and a new method of treatment is needed for these patients...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27879973/application-of-the-immunoscore-as-prognostic-tool-for-hepatocellular-carcinoma
#3
EDITORIAL
Annacarmen Petrizzo, Luigi Buonaguro
To date, the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) tumor, nodes, metastasis (TNM) classification represents the standard system for evaluation of prognosis in solid tumors. However, the clinical outcome can be significantly different in patients with the same TNM stage. Therefore, many efforts have been made aiming to define new prognostic parameters. Indeed, analyses conducted in large cohorts of colorectal cancer patients emphasized the prognostic value of tumor-infiltrating lymphocytes, leading to the development of a prognostic score referred to as "Immunoscore"...
2016: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/27872682/prophylactic-liver-transplantation-for-high-risk-recurrent-hepatocellular-carcinoma
#4
REVIEW
Po-Chih Yang, Cheng-Maw Ho, Rey-Heng Hu, Ming-Chih Ho, Yao-Ming Wu, Po-Huang Lee
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death in the world. Radical treatment of HCC in early stages results in a long disease-free period and improved overall survival. The choice of optimal management strategy for HCC mainly depends on the severity of the underlying liver disease. For patients with decompensated liver cirrhosis and HCC within Milan criteria (MC), liver transplant (LT) is the choice of treatment. However, for patients with good residual liver reserve and HCC within MC, selection of other curative treatments such as liver resection (LR) or radiofrequency ablation may be a reasonable alternative...
November 8, 2016: World Journal of Hepatology
https://www.readbyqxmd.com/read/27864623/simplified-hcc-art-score-for-highly-sensitive-detection-of-small-sized-and-early-stage-hepatocellular-carcinoma-in-the-widely-used-okuda-clip-and-bclc-staging-systems
#5
Abdelfattah M Attallah, Mohamed M Omran, Ahmed A Attallah, Mohamed A Abdelrazek, Khaled Farid, Ibrahim El-Dosoky
BACKGROUND: Small-sized HCC can be effectively cured by surgery with good clinical outcomes. A highly sensitive HCC α-fetoprotein routine test (HCC-ART) for HCC diagnosis as well as a simplied form of the HCC-ART were reported in the British Journal of Cancer. Here, we verified and studied the applicability of the HCC-ART to the detection of early-stage HCC. METHODS: 341 cirrhotic patients and 318 HCC patients were included in this study. For each, the HCC-ART score was calculated, and then the sensitivity, specificity, and results of an ROC curve analysis were compared between the HCC-ART and AFP when these biomarkers were used to detect small-sized HCC...
November 18, 2016: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27847278/validation-of-the-hong-kong-liver-cancer-staging-system-in-determining-prognosis-of-the-north-american-patients-following-intra-arterial-therapy
#6
Jae Ho Sohn, Rafael Duran, Yan Zhao, Florian Fleckenstein, Julius Chapiro, Sonia P Sahu, Rüdiger E Schernthaner, Tianchen Qian, Howard Lee, Li Zhao, James Hamilton, Constantine Frangakis, MingDe Lin, Riad Salem, Jean-Francois Geschwind
BACKGROUND & AIMS: There is debate over the best way to stage hepatocellular carcinoma (HCC). We attempted to validate the prognostic and clinical utility of the recently developed Hong Kong Liver Cancer (HKLC) staging system, a hepatitis B-based model, and compared data with that from the Barcelona Clinic Liver Cancer (BCLC) staging system in a North American population who underwent intra-arterial therapy (IAT). METHODS: We performed a retrospective analysis of data from 1009 patients with HCC who underwent intra-arterial therapy from 2000 through 2014...
November 12, 2016: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27847095/proteomic-analysis-and-translational-perspective-of-hepatocellular-carcinoma-identification-of-diagnostic-protein-biomarkers-by-an-onco-proteogenomics-approach
#7
REVIEW
Shyh-Horng Chiou, King-Teh Lee
Hepatocellular carcinoma (HCC) has been ranked as the third leading cause of cancer-related mortality worldwide. Typically, patients are already in advanced stages of liver cirrhosis at the time of HCC diagnosis. Because HCC is often detected at a late stage and is highly aggressive, noninvasive biomarkers are urgently needed for early diagnosis. Recent advances in gene-expression profiling technologies have enabled molecular classification of HCC into defined subclasses that provide a firm basis for further study of potential mechanisms and biomarkers underlying the development of HCC...
November 2016: Kaohsiung Journal of Medical Sciences
https://www.readbyqxmd.com/read/27842889/limitations-of-gd-eob-dtpa-enhanced-mri-can-clinical-parameters-predict-suboptimal-hepatobiliary-phase
#8
M Kobi, V Paroder, M Flusberg, A M Rozenblit, V Chernyak
AIM: To establish cut-off levels of the clinical parameters, which would predict suboptimal 30 minutes delayed hepatobiliary phase (HBP) with high specificity. MATERIALS AND METHODS: This retrospective study included patients with chronic liver disease who underwent hepatocellular carcinoma screening with Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI) between 1 January 2011 and 30 November 2014. For each case, HBP was graded as adequate or suboptimal, based on Liver Image Reporting and Data System (LI-RADS) criteria...
November 11, 2016: Clinical Radiology
https://www.readbyqxmd.com/read/27835609/incorporation-of-alpha-fetoprotein-afp-into-subclassification-of-bclc-c-stage-hepatocellular-carcinoma-according-to-a-5-year-survival-analysis-based-on-the-seer-database
#9
Nan Zhang, Jiajia Gu, Li Yin, Jing Wu, Ming-Yu Du, Kai Ding, Teng Huang, Xia He
PURPOSE: To evaluate the effect of serum alpha-fetoprotein(AFP) on prognosis of patients with hepatocellular carcinoma (HCC) and put forward a proposal to modify BCLC staging system and the recommended treatment of patients with stage C. RESULTS: AFP positive was an independent poor prognostic factor of HCC. Race, pathological grade, T stage, M stage were also regarded to be significant predicted factors for poorer prognosis. When combining AFP status with AJCC stage, patients with A1 disease had a worse prognosis compared with those with A0 disease within each stage...
November 9, 2016: Oncotarget
https://www.readbyqxmd.com/read/27830958/role-of-liver-directed-local-tumor-therapy-in-the-management-of-hepatocellular-carcinoma-with-extrahepatic-metastases-a-seer-database-analysis
#10
Omar Abdel-Rahman
BACKGROUND: This study assessed the prognostic impact of the liver-directed local tumor therapy in the management of hepatocellular carcinoma (HCC) with extrahepatic metastases. METHODS: Metastatic HCC patients diagnosed between 2004 and 2013 were identified from the SEER (Surveillance, Epidemiology, and End Results) database. Propensity-matched analysis was performed considering baseline characteristics (age, gender, race, histology, TNM stage, site of metastases, fibrosis score and alpha fetoprotein)...
November 21, 2016: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27827952/cell-free-rna-content-in-peripheral-blood-as-potential-biomarkers-for-detecting-circulating-tumor-cells-in-non-small-cell-lung-carcinoma
#11
Xin-Min Yu, Yi-Chen Wu, Xiang Liu, Xian-Cong Huang, Xiu-Xiu Hou, Jiu-Li Wang, Xiang-Liu Cheng, Wei-Min Mao, Zhi-Qiang Ling
Circulating tumor cells (CTCs) have been implicated in tumor progression and prognosis. Techniques detecting CTCs in the peripheral blood of patients with non-small cell lung carcinoma (NSCLC) may help to identify individuals likely to benefit from early systemic treatment. However, the detection of CTCs with a single marker is challenging, owing to low specificity and sensitivity and due to the heterogeneity and rareness of CTCs. Herein, the probability of cell-free RNA content in the peripheral blood as a potential biomarker for detecting CTCs in cancer patients was investigated...
November 5, 2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27821810/investigating-the-mechanism-of-hepatocellular-carcinoma-progression-by-constructing-genetic-and-epigenetic-networks-using-ngs-data-identification-and-big-database-mining-method
#12
Cheng-Wei Li, Ping-Yao Chang, Bor-Sen Chen
The mechanisms leading to the development and progression of hepatocellular carcinoma (HCC) are complicated and regulated genetically and epigenetically. The recent advancement in high-throughput sequencing has facilitated investigations into the role of genetic and epigenetic regulations in hepatocarcinogenesis. Therefore, we used systems biology and big database mining to construct genetic and epigenetic networks (GENs) using the information about mRNA, miRNA, and methylation profiles of HCC patients. Our approach involves analyzing gene regulatory networks (GRNs), protein-protein networks (PPINs), and epigenetic networks at different stages of hepatocarcinogenesis...
November 4, 2016: Oncotarget
https://www.readbyqxmd.com/read/27821083/single-administration-of-selective-internal-radiation-therapy-versus-continuous-treatment-with-sorafenib-in-locally-advanced-hepatocellular-carcinoma-sirvenib-study-protocol-for-a-phase-iii-randomized-controlled-trial
#13
Mihir Gandhi, Su Pin Choo, Choon Hua Thng, Say Beng Tan, Albert Su Chong Low, Peng Chung Cheow, Anthony Soon Whatt Goh, Kiang Hiong Tay, Richard Hoau Gong Lo, Brian Kim Poh Goh, Jen San Wong, David Chee Eng Ng, Khee Chee Soo, Wei Ming Liew, Pierce K H Chow
BACKGROUND: Approximately 20 % of hepatocellular carcinoma (HCC) patients diagnosed in the early stages may benefit from potentially curative ablative therapies such as surgical resection, transplantation or radiofrequency ablation. For patients not eligible for such options, prognosis is poor. Sorafenib and Selective Internal Radiation Therapy (SIRT) are clinically proven treatment options in patients with unresectable HCC, and this study aims to assess overall survival following either SIRT or Sorafenib therapy for locally advanced HCC patients...
November 7, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27816492/tremelimumab-in-combination-with-ablation-in-patients-with-advanced-hepatocellular-carcinoma
#14
Austin G Duffy, Susanna V Ulahannan, Oxana Makorova-Rusher, Osama Rahma, Heiner Wedemeyer, Drew Pratt, Jeremy L Davis, Marybeth S Hughes, Theo Heller, Mei ElGindi, Ashish Uppala, Firouzeh Korangy, David E Kleiner, William D Figg, David Venzon, Seth M Steinberg, Aradhana M Venkatesan, Venkatesh Krishnasamy, Nadine Abi-Jaoudeh, Elliot Levy, Brad J Wood, Tim F Greten
BACKGROUND: Tremelimumab is a fully human monoclonal antibody that binds to CTLA-4 on the surface of activated T lymphocytes. Ablative therapies have been shown to induce a peripheral immune response which may enhance the effect of anti-CTLA4 treatment in patients with advanced HCC. METHODS: Patients with HCC [Childs Pugh A/B7; Barcelona Clinic Liver Cancer Stage B/C; ECOG 0/1] were enrolled in a study of tremelimumab in combination with an ablative procedure performed during week 6...
November 2, 2016: Journal of Hepatology
https://www.readbyqxmd.com/read/27789901/assigning-treatment-to-hcc-patients-for-transplantation-utility-of-a-new-decision-making-tool
#15
Najmul Hassan Shah, Faisal Saud Dar, Abu Bakar Hafeez Bhatti, Atif Rana, Mohammad Salih
BACKGROUND The Barcelona clinic liver cancer (BCLC) staging system is considered the standard of care for hepatocellular carcinoma (HCC) management. It has various limitations, including lack of second-line treatment options and combination therapy. We prospectively collected data on our HCC patients based on a new decision-making tool (NDT). The objective of this study was to determine the applicability of this tool and compare it with BCLC for treatment allocation, in particular with respect to liver transplantation...
October 28, 2016: Annals of Transplantation: Quarterly of the Polish Transplantation Society
https://www.readbyqxmd.com/read/27785449/hepatocellular-carcinoma-a-review
#16
REVIEW
Julius Balogh, David Victor, Emad H Asham, Sherilyn Gordon Burroughs, Maha Boktour, Ashish Saharia, Xian Li, R Mark Ghobrial, Howard P Monsour
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and is a leading cause of cancer-related death worldwide. In the United States, HCC is the ninth leading cause of cancer deaths. Despite advances in prevention techniques, screening, and new technologies in both diagnosis and treatment, incidence and mortality continue to rise. Cirrhosis remains the most important risk factor for the development of HCC regardless of etiology. Hepatitis B and C are independent risk factors for the development of cirrhosis...
2016: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/27781198/novel-pretreatment-scoring-incorporating-c-reactive-protein-to-predict-overall-survival-in-advanced-hepatocellular-carcinoma-with-sorafenib-treatment
#17
Hiroyuki Nakanishi, Masayuki Kurosaki, Kaoru Tsuchiya, Yutaka Yasui, Mayu Higuchi, Tsubasa Yoshida, Yasuyuki Komiyama, Kenta Takaura, Tsuguru Hayashi, Konomi Kuwabara, Natsuko Nakakuki, Hitomi Takada, Masako Ueda, Nobuharu Tamaki, Shoko Suzuki, Jun Itakura, Yuka Takahashi, Namiki Izumi
OBJECTIVES: This study aimed to build a prediction score of prognosis for patients with advanced hepatocellular carcinoma (HCC) after sorafenib treatment. METHODS: A total of 165 patients with advanced HCC who were treated with sorafenib were analyzed. Readily available baseline factors were used to establish a scoring system for the prediction of survival. RESULTS: The median survival time (MST) was 14.2 months. The independent prognostic factors were C-reactive protein (CRP) <1...
October 2016: Liver Cancer
https://www.readbyqxmd.com/read/27775821/an-assessment-of-benefits-and-harms-of-hepatocellular-carcinoma-surveillance-in-patients-with-cirrhosis
#18
Omair Atiq, Jasmin Tiro, Adam C Yopp, Adam Muffler, Jorge A Marrero, Neehar D Parikh, Caitlin Murphy, Katharine McCallister, Amit G Singal
: Although surveillance ultrasound and alpha fetoprotein (AFP) have minimal direct harm, downstream harms from follow-up tests must be weighed against surveillance benefits when determining the value of hepatocellular carcinoma (HCC) screening programs. Our study's aims were to characterize prevalence and correlates of surveillance benefits and harms in cirrhosis patients undergoing HCC surveillance. We conducted a retrospective cohort study among patients with cirrhosis followed at a safety-net health system between July 2010 and July 2013...
October 24, 2016: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/27770556/survival-and-cost-effectiveness-of-sorafenib-therapy-in-advanced-hepatocellular-carcinoma-an-analysis-of-the-seer-medicare-database
#19
Neehar D Parikh, Vincent D Marshall, Amit G Singal, Hari Nathan, Anna S Lok, Rajesh Balkrishnan, Vahakn Shahinian
: Sorafenib is the only chemotherapeutic approved for treatment of advanced hepatocellular carcinoma (HCC.) However, its effectiveness in patients with Child Pugh B cirrhosis and any moderating effects of health system characteristics are unclear. We aimed to examine the survival and cost-effectiveness associated with sorafenib in elderly patients with advanced HCC. We performed an analysis of Medicare beneficiaries with HCC diagnoses from 2007-2009. We compared advanced stage patients with HCC (AJCC stage III/IV) who received sorafenib within 6 months of diagnosis (and were otherwise untreated) to advanced stage patients with HCC who received no therapy (control...
October 22, 2016: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/27766479/subclassification-of-patients-with-intermediate-stage-barcelona-clinic-liver-cancer-stage-b-hepatocellular-carcinoma-using-the-up-to-seven-criteria-and-serum-tumor-markers
#20
Haruki Kimura, Kazuyoshi Ohkawa, Masanori Miyazaki, Mitsuru Sakakibara, Kazuho Imanaka, Takeshi Tamura, Hironari Sueyoshi, Ryoji Takada, Nobuyasu Fukutake, Hiroyuki Uehara, Reiko Ashida, Tatsuya Ioka, Tetsuro Nakazawa, Katsuyuki Nakanishi, Kazuhiro Katayama
BACKGROUND: Intermediate-stage [Barcelona Clinic Liver Cancer stage-B (BCLC-B)] hepatocellular carcinoma (HCC) comprises of a heterogeneous population of patients with a wide range of tumor burdens. We therefore formulated a subclassification of BCLC-B HCC using the up-to-seven criteria and tumor markers according to the results of a retrospective analysis of these patients. METHODS: This study included 125 patients newly diagnosed with BCLC-B HCC who underwent transarterial chemoembolization...
October 20, 2016: Hepatology International
keyword
keyword
66281
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"